Ascendis Pharma A/S
F:A71
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Ascendis Pharma A/S
F:A71
|
DK |
|
V
|
Viking Therapeutics Inc
F:1VT
|
US |
|
A
|
Adaro Energy Indonesia TBK PT
SWB:A64
|
ID |
|
N
|
Nordson Corp
F:ND1
|
US |
|
B
|
Banco Bilbao Vizcaya Argentaria SA
DUS:BOY
|
ES |
|
C
|
Commercial Metals Co
F:CMS
|
US |
|
T
|
Tetra Tech Inc
F:TT6
|
US |
|
W
|
Westpac Banking Corp
F:WBC
|
AU |
|
C
|
Crown Holdings Inc
F:CWN
|
US |
|
Clover Health Investments Corp
NASDAQ:CLOV
|
US |
|
L
|
Lime Technologies AB (publ)
F:LTX
|
SE |
|
F
|
Fulton Financial Corp
F:FU5
|
US |
|
Atoss Software AG
F:AOF
|
DE |
Wall St Price Targets
A71 Price Targets Summary
Ascendis Pharma A/S
According to Wall Street analysts, the average 1-year price target for A71 is 228.55 EUR with a low forecast of 193.38 EUR and a high forecast of 278.79 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is A71's stock price target?
Price Target
228.55
EUR
According to Wall Street analysts, the average 1-year price target for A71 is 228.55 EUR with a low forecast of 193.38 EUR and a high forecast of 278.79 EUR.
What is the Revenue forecast for Ascendis Pharma A/S?
Projected CAGR
24%
Over the last 12 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 24%.
What is the Gross Profit forecast for Ascendis Pharma A/S?
Projected CAGR
25%
The compound annual growth rate for Gross Profit over the next 8 years is 25%.
